CMSC: Clinical realization and commercialization explosion are imminent, and Chinese AI pharmaceuticals stand out in global competition.

CMSC has released a research report indicating that AI drug development has entered the clinical verification stage and is poised for a commercial explosion. At a time when the competitive landscape of traditional drug development is still being reshaped by AI, Chinese AIBiotech has already achieved early positioning and is rapidly validating its commercial value; Chinese AI pharmaceutical companies have entered the market early, leveraging the advantages of China's AI industry ecosystem to stand out in the global AI drug development competition. Key points from CMSC are as follows: AI drug development validation levels continue to rise, and the commercial viability is becoming apparent. Since 2024, the pace of AI drug development has noticeably accelerated, with a significant increase in both investment scale and quantity. Multinational corporations (MNCs) are making large-scale investments in their own AI platform capabilities, shifting from point collaborations to pipeline and platform collaborations. AI technology giants are entering the drug development arena, launching specialized AI models for drug development based on general large models. The scale and opportunities for AIBiotech partnerships have significantly increased, attracting interest from traditional pharmaceutical companies even in the absence of a mature commercial pipeline. AI drug development has completed concept validation and has officially entered the clinical verification stage, with preliminary signs of commercialization emerging. AI drug development clinical pipelines are advancing rapidly, and key assets are expected to achieve commercialization within three to five years. The database of the institution includes 94 AI drugs that have entered clinical trials, with key assets analyzed. AI empowerment has significantly shortened drug development cycles, enhancing drug affinity and selectivity during the early screening and design phases, resulting in a high overall quality and rapid advancement of clinical pipelines. The seven fastest-progressing key assets have all entered or completed Phase III clinical trials and will gradually be commercialized in the next three to five years. INSILICO's Rentosertib and Takeda's Zasocitinib are pipelines with potential Best in Class (BIC) and orphan drug designations, exemplifying the current AI drug development capabilities and quality levels, warranting close attention. AI is reshaping the competitive landscape of drug development, with Chinese AIBiotech breaking through through pipeline research collaboration and platform services. In recent years, global large MNCs have intensively engaged in the AI drug development field, closely collaborating with AI giants such as OpenAI, Google, Anthropic, and NVIDIA to build AI-driven research platforms. This creates a new competitive moat based on an "AI model-computing power-experimental data" research loop, establishing long-term technological barriers. Chinese AIBiotech possesses advantages in power infrastructure, computing power, and specialized AI research models, focusing on advancing self-developed pipelines, pipeline research collaborations, and platform licenses to accelerate the verification of its self-developed AI platform's research capabilities and commercial value. At a time when the traditional drug development competitive landscape reshaped by AI is not yet fully formed, Chinese AIBiotech has already established early positioning and is rapidly validating its commercial value. Focus on companies and future catalysts. Chinese AI pharmaceutical companies entered the market early, leveraging China's AI industry ecosystem advantages to stand out in the global AI drug development competition. INSILICO: A pioneer in AI drug development, leveraging its self-developed end-to-end platform Pharma.AI to empower drug research. Jingtai Technology: Extending platform capabilities to drug development, chemicals, etc., achieving commercial profitability. Jitai Technology: Focusing on drug-targeted delivery technology based on its self-developed AI nano-foundation large model. Biocytogen Pharmaceuticals: Developing an AI-driven antibody discovery platform RenSuperWorkstation to empower preclinical contract research organizations (CROs) and biotechnology services. Baitu Biotechnology: Developing a life sciences large model xTrimo V3 to support research across multiple fields. VIVA BIOTECH: An integrated AIDD platform empowering one-stop CXO services. Hitgen Inc.: Building an integrated AI-driven molecular optimization platform with its globally leading DEL library. PharmaResources: Developing the DiOrion platform to cover the complete early research process of new drugs. Cathay Biotech Inc.: Driving a transformation in research models in synthetic biology with "AI + biomanufacturing." KingStar Biotechnology: An AI-driven automated factory enabling large-scale production to open up global markets. Twist Bioscience: A leading DNA synthesis company in the US creating AI-scaled antibody discovery production services. Risk warnings: Risks of research underperformance, risks of commercialization underperformance, data security risks, risks of payment policy changes, intensifying competition risks.